Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target

Fig. 4

The tumorigenic role of LGR5 in ER− BC. a Gene expression profiles in control and LGR5-KD MDA-MB-231 (MDA) cell lines. KD of LGR5 downregulates canonical Wnt pathway genes, such as β-catenin and Cyclin D (n = 3, Mean ± SD, Student t-test, **P < 0.01, ***P < 0.001). b Colony assay as a surrogate for tumor initiating capacity using single MDA-ctrl and MDA-LGR5KD cells in 3D culture showing number of spheres across increasing days in culture. KD of LGR5 significantly reduces sphere formation when compared to MDA-ctrl (n = 3, Mean ± SD, Student t-test, *P < 0.05, **P < 0.01, ****P < 0.0001). c Representative images from resected tumors of 1 × 106 MDA cells transplanted in Matrigel that were allowed to grow in the inguinal mammary gland for 6 weeks. d Weights of resected tumors from MDA-ctrl (n = 4) and MDA-LGR5KD cell lines (n = 4) shows that KD of LGR5 attenuates tumor growth. Mean ± SD. (Student t-test, *P < 0.05)

Back to article page